UMIN-ICDS Clinical Trial

Unique ID issued by UMIN UMIN000048117
Receipt number R000054840
Scientific Title Study on the improvement effect of amino acids containing supplement on kidney function
Date of disclosure of the study information 2022/06/21
Last modified on 2022/12/20 11:58:08

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Study on the improvement effect of amino acids containing supplement on kidney function

Acronym

Study on the improvement effect of amino acids containing supplement on kidney function

Scientific Title

Study on the improvement effect of amino acids containing supplement on kidney function

Scientific Title:Acronym

Study on the improvement effect of amino acids containing supplement on kidney function

Region

Japan


Condition

Condition

Healthy Adults

Classification by specialty

Not applicable

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

To examine the improvement effect of 12-week continuous ingestion of amino acids containing supplement on kidney function in 20 to 64 years old adults

Basic objectives2

Efficacy

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

Estimated glomerular filtration rate cystatin C (eGFRcys)
Estimated glomerular filtration rate creatinine (eGFRcrea)

Key secondary outcomes

Proteinuria
Urinary glucose
Hematuria
Urinary creatinine
Urinary albumin
Subjective fatigue and sleeping
Sleep habit


Base

Study type

Interventional


Study design

Basic design

Parallel

Randomization

Randomized

Randomization unit

Individual

Blinding

Double blind -all involved are blinded

Control

Placebo

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

2

Purpose of intervention

Prevention

Type of intervention

Food

Interventions/Control_1

Ingest 2 tablets of the test food (amino acids containing supplement) each after breakfast and dinner daily for 12 weeks

Interventions/Control_2

Ingest 2 tablets of the placebo food (dextrin) each after breakfast and dinner daily for 12 weeks

Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit

64 years-old >=

Gender

Male and Female

Key inclusion criteria

1. Persons who provide written informed consent
2. Healthy Japanese who are 20 years old or more and under 64 years old
3. Persons with eGFRcys values in the bottom 40 at screening

Key exclusion criteria

1. Persons who have any chronic illnesses with medication and who have any serious disease histories
2. Persons who are classified in moderate risk or higher (orange or red) of CKD stages
3. Persons who are classified in G3a of GFR categories and under 40 years old
4. Persons who are classified in G1 or G2 of GFR categories, and present with mild proteinuria(0.15~0.49 g/gCr)and hematuria
5. Persons who have a history of CKD diagnosed by markers of kidney damage (albuminuria (AER more thatn 30mg/24 hours; ACR more than 30mg/gCr), urine sediment abnormalities, electrolyte and other abnormalities due to tubular disorders, abnormalities detected by histology, structural abnormalities detected by imaging, or history of kidney transplantation)
6. Persons who have any allergies to the ingredients used in the test food
7. Persons who regularly use medicines or foods with health claims (foods for specified health use, foods with functional claims and foods with nutritional claims) etc., that may affect renal function
8. Persons who have participated in other tests within the past one month before the start of test, or those who intend to participate in another exam after consenting to the exam
9. Persons who were judged as inappropriate for study participant by the principal investigator
10. Persons who are breast-feeding, pregnant and planning or wishing to become pregnant during the study period

Target sample size

40


Research contact person

Name of lead principal investigator

1st name Chihiro
Middle name
Last name Nagayama

Organization

Healthcare Systems Co., Ltd.

Division name

Clinical Research Department

Zip code

105-0004

Address

Nisshin Tatemono Shinbashi Bld. 7F, 4-6-15 Shinbashi, Minato-ku, Tokyo, JAPAN

TEL

03-6809-2722

Email

nagayama.chihiro@hc-sys.jp


Public contact

Name of contact person

1st name Chihiro
Middle name
Last name Nagayama

Organization

Healthcare Systems Co., Ltd.

Division name

Clinical Research Department

Zip code

105-0004

Address

Nisshin Tatemono Shinbashi Bld. 7F, 4-6-15 Shinbashi, Minato-ku, Tokyo, JAPAN

TEL

03-6809-2722

Homepage URL


Email

nagayama.chihiro@hc-sys.jp


Sponsor or person

Institute

Healthcare Systems Co., Ltd.

Institute

Department

Personal name



Funding Source

Organization

Igakukobo Inc.

Organization

Division

Category of Funding Organization

Profit organization

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

The Ethics Committee of Healthcare Systems Co., Ltd.

Address

Nisshin Tatemono Shinbashi Bld. 7F, 4-6-15 Shinbashi, Minato-ku, Tokyo, JAPAN

Tel

03-6809-2722

Email

soumu@hc-sys.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2022 Year 06 Month 21 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled

40

Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Completed

Date of protocol fixation

2022 Year 06 Month 16 Day

Date of IRB

2022 Year 06 Month 16 Day

Anticipated trial start date

2022 Year 08 Month 25 Day

Last follow-up date

2022 Year 12 Month 12 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2022 Year 06 Month 21 Day

Last modified on

2022 Year 12 Month 20 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/icdr_e/ctr_view.cgi?recptno=R000054840


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name